The APP/FE65 Complex in Regulating Neurite Outgrowth

About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
April 01, 2004 - September 30, 2006
Grant ID
A2004255
Summary
Alzheimer’s disease (AD) is believed to be caused by the excess accumulation of amyloid beta (Aß) in the brain. It is well known that Aß is derived through the processing of a larger molecule, the amyloid precursor protein (APP). Determining the function of APP will further an understanding of the pathological events leading to AD and should help to identify therapeutic targets that do not disrupt normal brain functions. Dr. Ikin believes that proteins that bind to APP could potentially modify its function. One such protein is the cytosolic adapter FE65. Dr. Ikin has already shown that APP and FE65 both localize in a region of neuronal growth cones along with mena, which regulates membrane motility and is required for normal neural development. This suggests that a constellation of factors involving APP and FE65 may play a role in growth cone motility. In this project, Dr. Ikin is testing the hypothesis that APP, FE65, and one or more additional proteins form a complex involved in the regulation of growth cone movement and neurite outgrowth. The function of this complex may have direct implications for AD, since the loss of neural connections and neuronal sprouting are prominent features of Alzheimer’s disease pathology.
Related Grants
Alzheimer's Disease Research
Repairing the Body Clock to Delay Alzheimer's Disease
Active Dates
July 01, 2025 - June 30, 2028
Principal Investigator
Jae-eun Miller, Ph.D.
Current Organization
The Trustees of Columbia University in the City of New York
Repairing the Body Clock to Delay Alzheimer's Disease
Active Dates
July 01, 2025 - June 30, 2028
Principal Investigator
Jae-eun Miller, Ph.D.
Current Organization
The Trustees of Columbia University in the City of New York
Alzheimer's Disease Research
CXCR3 chemokine receptor blockade as a therapy for CNS T-cell infiltration in tauopathy and neurodegeneration
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Joshua Emmerson, Ph.D.
Current Organization
Washington University in St.Louis
CXCR3 chemokine receptor blockade as a therapy for CNS T-cell infiltration in tauopathy and neurodegeneration
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Joshua Emmerson, Ph.D.
Current Organization
Washington University in St.Louis
Alzheimer's Disease Research
Ultrasound Treatment to Replenish Cells Essential for Brain Function
Active Dates
July 01, 2025 - June 30, 2028
Principal Investigator
Isabelle Aubert, PhD
Current Organization
Sunnybrook Research Institute
Ultrasound Treatment to Replenish Cells Essential for Brain Function
Active Dates
July 01, 2025 - June 30, 2028

Principal Investigator
Isabelle Aubert, PhD
Current Organization
Sunnybrook Research Institute